Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.
|
| Abstract |
Acute erythroleukemia (AML-M6) is an uncommon subtype of acute myeloid leukemia (AML); it is considered to have a poor prognosis. From 1 January 1980 to 21 May 2008, 91 patients with newly diagnosed AML-M6 were seen at the University of Texas-M.D. Anderson Cancer Center (UT-MDACC). Forty-five patients (50%) had a history of myelodysplatic syndrome (MDS), compared with 41% in our control group (patients with other AML subtypes) (P=0.08). Poor-risk cytogenetics were more common in patients with AML-M6 (61% versus 38%, P=0.001). Complete remission rates were 62% for patients with AML-M6, comparing with 58% for the control group (P=0.35). Median disease free survival (DFS) for patients with AML-M6 was 32 weeks, versus 49 weeks for the control group (P=0.05). Median overall survival (OS) of patients with AML-M6 was 36 weeks, compared with 43 weeks for the control group (P=0.60). On multivariate analysis for DFS and OS, AML-M6 was not an independent risk factor. AML-M6 is commonly associated with a previous diagnosis of MDS and poor-risk karyotype. The diagnosis of AML-M6 does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well known AML prognostic factors.
|
|---|---|
| Authors | F P S Santos, S Faderl, G Garcia-Manero, C Koller, M Beran, S O'Brien, S Pierce, E J Freireich, X Huang, G Borthakur, C Bueso-Ramos, M de Lima, M Keating, J Cortes, H Kantarjian, F Ravandi |
| Journal | Leukemia (Leukemia) Vol. 23 Issue 12 Pg. 2275-80 (Dec 2009) ISSN: 1476-5551 [Electronic] England |
| PMID | 19741728 (Publication Type: Journal Article) |
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!